-
Suitability of Measures of Pharmacy-Based Medication Adherence for Routine Clinical Use Among Patients with Chronic Diseases: A Systematic Review
30 Jan 2025 14:33 GMT
… medication adherence serve as the basis for developing … of antihypertensive drugs among patients … to Hypertension Medication: the HYVALUE Randomized Clinical Trial. … treatment in a community health center by utilizing medication possession ratio. Pharmacia …
-
Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment
30 Jan 2025 14:33 GMT
… intravitreal ranibizumab injection (IRI) treatment. Additionally, this study … sex distribution, history of hypertension, history of diabetes, RVO … highly correlated with the development of ME and the … growth factor therapy for treating macular edema resulting …
-
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
30 Jan 2025 11:30 GMT
… no currently approved treatments.” “These therapeutic … (Pulmonary Arterial Hypertension, “PAH”) medications have been … with optimized pharmacokinetics and biophysical … developing biologic medicines that overcome the existing challenges of GPCR-targeted drug …
-
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
30 Jan 2025 12:20 GMT
… placebo-controlled clinical trial to evaluate WINREVAIR … FDA-approved for the treatment of adults with pulmonary arterial hypertension … the impact of pharmaceutical industry regulation and … inherent in new product development, including obtaining regulatory …
-
Merck to stop lung condition drug study early due to strong efficacy data
30 Jan 2025 12:49 GMT
… study testing its drug to treat pulmonary arterial hypertension (PAH) ahead … is already approved for treating the rare condition which … its top-selling cancer treatment Keytruda from close copies. … background PAH therapy.
The trial participants would be able …
-
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
30 Jan 2025 14:25 GMT
… Daily Life Scale, a treatment effect with a nominal p … which it is developing for pulmonary arterial hypertension. The biotech will … ’s study.
Fellow Big Pharma Johnson & Johnson has … “novel mechanisms to modify, treat and/or prevent neurodegenerative …
-
GLP-1 drug approvals: A breakdown
30 Jan 2025 01:17 GMT
As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
The approved indications for brand-name GLP-1s:
Adlyxin (lixisenatide)
Type 2 …
-
New link revealed between hypertension and the gut
29 Jan 2025 21:30 GMT
… human clinical trial to better understand gut permeability in hypertension, and is … drugs to bind to the receptors.
“We have partnered with computational drug … new drugs to activate these receptors, opening opportunities for new treatments that …
-
Are YOU at risk of developing young-onset dementia? Experts reveal the terrifying hidden risks and the very simple steps you can take to avoid them
29 Jan 2025 20:15 GMT
… .
‘If you develop, say, type 2 diabetes and hypertension earlier in life … .
The good news is that treating it will reduce that risk … .
It isn’t clear if treatment can reduce your risk once … those taking other anti-diabetic medication.
But the best way to …
-
Federal Circuit Reverses Decision Finding Lack of Written Description for Patent Claiming a Pharmaceutical Composition Comprising the Two Active Ingredients in Entresto®
29 Jan 2025 18:16 GMT
… drug used to treat heart failure.
Following a three-day bench trial … was approved for the treatment of heart failure with … an animal model of hypertension and heart failure, … appropriate claim construction when developing arguments regarding written description …
About
© 1995-2025